Compiled by Rupeestop LLP, SEBI RIA INA000022701. NAV as on 01 Oct 2026. Factsheet May 2026. About · Disclosures
Nippon India Pharma Fund Direct Plan Dividend Plan IDCW Payout
Nippon India Mutual FundSectoral Pharma and HealthcareDirectIDCWModerate risk
NAV
₹171.9818
As on 01 Oct 2026
Vs category
| Period | This fund | Category | Rank |
|---|---|---|---|
| 1 year | +4.14% | — | — |
| 3 year | +9.39% | — | — |
| 5 year | +7.46% | — | — |
- Sharpe
- 0.83
- Std dev
- 14.82%
- Beta
- 0.89
Returns
From NAVs through 01 Oct 2026
1Y
+4.14%
Total
3Y
+9.39%
p.a.
5Y
+7.46%
p.a.
SI
+8.10%
p.a.
Calendar years
-12.05%2022
+40.36%2023
+26.95%2024
-10.14%2025
+2.21%2026 YTD
Rolling 1-year · 51 overlapping windows
-15.75%avg +11.81%+56.39%
Fund facts
Fund details from the May 2026 factsheet
Fund size
₹8,365.40 Cr
As on 30-Apr-2026
Expense ratio
0.80%
Direct 0.80% · Regular 1.52%
Min SIP
₹5000 & in multiples of ₹1
Exit load
None
Lock-in
None
BenchmarkBSE Healthcare TRI
Launched05 Jun 2004
Risk levelModerate
StructureOpen Ended
AAUM₹8,085.70 Cr
Entry loadNone
ISININF204K01I35
Where the money is invested
Split by asset type and company size.
By asset type
Equity98.68%
Cash1.32%
By company size
Large Cap42.00%
Small Cap30.00%
Mid Cap28.00%
What the fund holds
44 holdings · portfolio as on 29 Apr 2026
- 13.85%Sun Pharmaceutical Industries LimitedPharmaceuticals & Biotechnology
- 13.85%Sun Pharmaceuticals Industries LtdHealthcare
- 7.95%Lupin LimitedPharmaceuticals & Biotechnology
- 7.04%Dr. Reddy's Laboratories LimitedPharmaceuticals & Biotechnology
- 6.61%Divi's Laboratories LimitedPharmaceuticals & Biotechnology
- 5.47%Cipla LimitedPharmaceuticals & Biotechnology
- 5.01%Apollo Hospitals Enterprise LimitedHealthcare Services
- 4.75%Equity Less Than 1% of Corpus
- 3.78%Medplus Health Services LimitedRetailing
- 3.36%Vijaya Diagnostic Centre LimitedHealthcare Services
Concentration
Top 5 weight
40.92%
Top 10 weight
59.53%
Avg turnover
46.87%
Risk and quality measures
How steady the returns have been.
Return quality
Sharpe
0.83
Below category avg 0.99
Sortino
0.27
Return per unit of downside risk
Alpha
-0.38
Return above the benchmark
Risk
Std deviation
14.82%
How much returns swing
Beta
0.89
Better than category avg 0.96
R-squared
94.8%
How closely it tracks the benchmark
Who manages this fund
3 fund managers
- LMLokesh Maru0.5 years in the industryRuns 43 schemes
- SRSailesh Raj Bhan20.9 years in the industryManaging since Jun-2004Runs 7 schemes
- DDDivya Dutt Sharma0.5 years in the industryRuns 43 schemes
SIP illustration
Rate
+9.39%
Invested
₹6,00,000
Illustrated
₹9,97,148
₹5,000/mo × 10 years at this fund's 3Y CAGR. Illustration, not a forecast. SIP calculator
FAQ
What is Nippon India Pharma Fund Direct Plan Dividend Plan IDCW Payout NAV today?
- The latest NAV of Nippon India Pharma Fund Direct Plan Dividend Plan IDCW Payout is ₹171.9818 as on 01 Oct 2026.
How has Nippon India Pharma Fund Direct Plan Dividend Plan IDCW Payout performed vs its category?
- 1-year return +4.14%. Past performance does not guarantee future returns.
What are the returns of Nippon India Pharma Fund Direct Plan Dividend Plan IDCW Payout?
- Trailing returns from published NAVs: 1 year +4.14%, 3 year +9.39% a year, 5 year +7.46% a year, since our first NAV +8.10% a year. Past performance does not guarantee future returns.
How would a SIP in Nippon India Pharma Fund Direct Plan Dividend Plan IDCW Payout have been illustrated?
- The SIP illustration on this page uses ₹5,000 a month for 10 years at this fund's 3-year annualised return of +9.39%. It is not a forecast.
What is the expense ratio and fund size of Nippon India Pharma Fund Direct Plan Dividend Plan IDCW Payout?
- For Nippon India Pharma Fund Direct Plan Dividend Plan IDCW Payout, the expense ratio is 0.80% and fund size (AUM) is ₹8,365.40 Cr.
What is the ISIN of Nippon India Pharma Fund Direct Plan Dividend Plan IDCW Payout?
- The ISIN for Nippon India Pharma Fund Direct Plan Dividend Plan IDCW Payout is INF204K01I35.
Mutual fund investments are subject to market risks. Read all scheme related documents carefully before investing. Past performance does not guarantee future returns and is not an indicator of future results.
Figures on this page come from published NAVs and the scheme's monthly factsheet. They are for information only and are not investment advice or a recommendation to buy or sell any scheme.